{"abstract": "The drug Xtandi, already on the market for post-chemotherapy use, could open a new front in its competition with Johnson & Johnson\u2019s Zytiga.", "web_url": "https://www.nytimes.com/2014/01/29/health/drug-shows-promise-in-advanced-prostate-cancer-when-used-before-chemotherapy.html", "snippet": "The drug Xtandi, already on the market for post-chemotherapy use, could open a new front in its competition with Johnson & Johnson\u2019s Zytiga.", "lead_paragraph": "The prostate cancer drug Xtandi prolonged lives and delayed tumor progression when used before chemotherapy in a study of men with advanced cases of the disease, researchers said on Tuesday.", "print_section": "B", "print_page": "3", "source": "The New York Times", "multimedia": [], "headline": {"main": "Drug Shows Promise in Advanced Prostate Cancer When Used Before Chemotherapy", "kicker": null, "content_kicker": null, "print_headline": "Drug Shows Promise in Advanced Prostate Cancer When Used Before Chemotherapy", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "persons", "value": "Pollack, Andrew", "rank": 1, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 2, "major": "N"}, {"name": "subject", "value": "Prostate Cancer", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Medivation Inc", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Astellas Pharma", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Johnson & Johnson", "rank": 6, "major": "N"}], "pub_date": "2014-01-29T02:17:02+0000", "document_type": "article", "news_desk": "Business", "section_name": "Health", "byline": {"original": "By Andrew Pollack", "person": [{"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/8d551cb6-5f52-54d4-aefb-8aeaf4864d42", "word_count": 487, "uri": "nyt://article/8d551cb6-5f52-54d4-aefb-8aeaf4864d42"}